Children receiving intensive chemotherapy benefit from prophylaxis with levofloxacin to an extent that would justify the cost of the drug, a new analysis finds.
Levofloxacin prophylaxis is a cost-effective therapy for children with leukemia who receive intensive chemotherapy, according to a new study.
Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have high overall survival (OS) rates, of 90% and 60%-65%, respectively. Among the minority of patients who do not survive, serious bacterial infection is a common culprit. The risk of such infections is particularly high in patients who undergo intensive chemotherapy.
Corresponding author Marie-Claude Pelland-Marcotte, MD, of The Hospital for Sick Children, in Toronto, and colleagues wanted to evaluate whether giving children with ALL and AML levofloxacin (Levaquin) as a prophylactic might be a cost-effective method by which to avoid infection and infection-related morbidity and mortality. They reported their findings in the journal Pediatric Blood & Cancer.
Pelland-Marcotte and colleagues performed a literature review and identified a single randomized controlled trial that looked at levofloxacin prophylaxis in childhood AML and relapsed ALL. The study showed rates of fever and neutropenia were lower among children given the drug compared to those who did not receive prophylaxis, 71.2% versus 82.1%. Rates of bacteremia were also lower, at 21.9% among the levofloxacin arm compared to 43.4% among those receiving no prophylaxis.
Using those data as a backdrop, Pelland-Marcotte and colleagues performed a cost-utility analysis to see whether the impact of levofloxacin justified its cost.
They found that use of levofloxacin resulted in a cost savings of $542.44. Patients receiving the drug also had an increased survival of 0.13 quality-adjusted life years (QALYs).
“The direct cost of antibiotic prophylaxis and its side effects were relatively minor compared to its benefits,” the authors wrote.
The investigators added that on their probabilistic sensitivity analysis, the probability of the prophylaxis not being cost effective was less than 1%, using a willingness to pay threshold of $50,000.
One question that remains unanswered is whether the cost-effectiveness of the prophylaxis might change if patients receive multiple cycles of chemotherapy. The authors said there’s a chance the cost effectiveness would increase over multiple cycles, though they said other factors must also be considered.
“It is also possible that prolonged exposure to levofloxacin over more than two cycles of chemotherapy increases the risk of antibacterial resistance and adverse effects,” they wrote.
Though they said the decision of whether or not to administer levofloxacin as a prophylactic should ultimately be based on clinical factors, the authors believe the economic case is strong.
Another issue that may impact decisions, however, is the effort by many hospitals to implement policies that restrict antibiotic use in order to protect against drug resistance.
Pelland-Marcotte and colleagues calculated that the risk of resistant infections would not change their bottom line conclusion that levofloxacin prophylaxis has a favorable cost/benefit ratio.
“Nonetheless, further research about short- and long-term antimicrobial resistance following antibiotic prophylaxis is greatly needed,” they said.
Another question raised by the study is whether parents would be amenable to the use of the drug. The authors said previous research on parents’ willingness to pay thresholds for a prophylactic suggests the drug would still be cost-effective, particularly if most patients received the drug orally, as opposed to intravenously.
Lastly, the authors noted that while the data in the study was based on Canadian patients, they expect the findings would be generalizable to other countries. However, they said it is not yet known if the findings would be generalizable to other types of cancer or therapy.
Reference
Maser B, Pelland-Marcotte MC, Alexander S, Sung L, Gupta S. Levofloxacin prophylaxis in hospitalized children with leukemia: A cost-utility analysis. Pediatr Blood Cancer. Published online August 12, 2020. doi:10.1002/pbc.28643
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More